Mostrar o rexistro simple do ítem

dc.contributor.authorGarcia-Gutiérrez, V.
dc.contributor.authorLuna, A.
dc.contributor.authorAlonso-Dominguez, J.M.
dc.contributor.authorEstrada, N.
dc.contributor.authorBoque, C.
dc.contributor.authorXicoy, B.
dc.contributor.authorGiraldo, P.
dc.contributor.authorAngona, A.
dc.contributor.authorAlvarez-Larrán, A.
dc.contributor.authorSanchez-Guijo, F.
dc.contributor.authorRamírez, M.J.
dc.contributor.authorMora, E.
dc.contributor.authorVélez, P.
dc.contributor.authorRosell, A.
dc.contributor.authorColorado Araujo, M.
dc.contributor.authorCuevas, B.
dc.contributor.authorSagüés, M.
dc.contributor.authorCortes, M.
dc.contributor.authorPérez Encinas, Manuel Mateo 
dc.contributor.authorCasado Montero, L.F.
dc.contributor.authorMoreno Vega, M.
dc.contributor.authorSerrano, L.
dc.contributor.authorGomez, V.
dc.contributor.authorGarcia-Hernandez, C.
dc.contributor.authorLakhwani, S.
dc.contributor.authorPaz Coll, A.
dc.contributor.authorde Paz, R.
dc.contributor.authorSuarez-Varela, S.
dc.contributor.authorFernandez-Ruiz, A.
dc.contributor.authorPerez Lopez, R.
dc.contributor.authorOrtiz-Fernández, A.
dc.contributor.authorJiménez-Velasco, A.
dc.contributor.authorSteegmann-Olmedillas, J.L.
dc.contributor.authorHernández-Boluda, J.C.
dc.date.accessioned2025-08-12T11:28:12Z
dc.date.available2025-08-12T11:28:12Z
dc.date.issued2021
dc.identifier.citationGarcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer Journal. 2021;11(2)
dc.identifier.issn2044-5385
dc.identifier.otherhttps://sergas.portalcientifico.es//documentos/605a0f863d93f26dffb4e27a
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20381
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdult *
dc.subject.meshAged *
dc.subject.meshAged, 80 and over *
dc.subject.meshFemale *
dc.subject.meshFusion Proteins, bcr-abl*
dc.subject.meshHumans *
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive *
dc.subject.meshMale *
dc.subject.meshMiddle Aged *
dc.subject.meshNiacinamide *
dc.subject.meshProtein Kinase Inhibitors *
dc.subject.meshPyrazoles *
dc.subject.meshTreatment Outcome *
dc.subject.meshYoung Adult *
dc.titleSafety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
dc.typeArticle
dc.rights.licenseAtribución 4.0 Internacional*
dc.authorsophosGarcia-Gutiérrez, V.
dc.authorsophosLuna, A.
dc.authorsophosAlonso-Dominguez, J.M.
dc.authorsophosEstrada, N.
dc.authorsophosBoque, C.
dc.authorsophosXicoy, B.
dc.authorsophosGiraldo, P.
dc.authorsophosAngona, A.
dc.authorsophosAlvarez-Larrán, A.
dc.authorsophosSanchez-Guijo, F.
dc.authorsophosRamírez, M.J.
dc.authorsophosMora, E.
dc.authorsophosVélez, P.
dc.authorsophosRosell, A.
dc.authorsophosColorado Araujo, M.
dc.authorsophosCuevas, B.
dc.authorsophosSagüés, M.
dc.authorsophosCortes, M.
dc.authorsophosEncinas, M.P.
dc.authorsophosCasado Montero, L.F.
dc.authorsophosMoreno Vega, M.
dc.authorsophosSerrano, L.
dc.authorsophosGomez, V.
dc.authorsophosGarcia-Hernandez, C.
dc.authorsophosLakhwani, S.
dc.authorsophosPaz Coll, A.
dc.authorsophosde Paz, R.
dc.authorsophosSuarez-Varela, S.
dc.authorsophosFernandez-Ruiz, A.
dc.authorsophosPerez Lopez, R.
dc.authorsophosOrtiz-Fernández, A.
dc.authorsophosJiménez-Velasco, A.
dc.authorsophosSteegmann-Olmedillas, J.L.
dc.authorsophosHernández-Boluda, J.C.
dc.identifier.doi10.1038/S41408-021-00420-8
dc.identifier.sophos605a0f863d93f26dffb4e27a
dc.issue.number2
dc.journal.titleBlood Cancer Journalen
dc.relation.publisherversionhttps://doi.org/10.1038/s41408-021-00420-8
dc.rights.accessRightsopenAccess*
dc.subject.keywordAS Santiago AP
dc.subject.keywordCHUS
dc.typefidesArtículo de Opinión
dc.typesophosArtículo Original
dc.volume.number11


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional